Track market-moving stories before they get noisy

REITs are looking increasingly compelling in the current environment. I detail my favorite 7%+ yielding REIT investment opportunities right now. I share the risks and the upside potential for both of them.

April 15, 2026 16:15 ET  | Source: Royalty Pharma plc

NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Conference Call Information

Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 19 development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6637
[email protected]

April 21, 2026 13:00 ET  | Source: Royalty Pharma plc

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in translational medicine. The Prize will honor scientific breakthroughs that bridge the gap between fundamental discovery and the development of new medicines that improve and extend patients’ lives. It will include a $1 million award distributed among one or more established scientists whose work has translated unique scientific insights into medicines with significant impact, particularly contributions not yet recognized by the field’s most prominent awards.

“Royalty Pharma believes that scientific discovery can transform patient lives when it is successfully translated into medicines,” said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. “With the Royalty Pharma Translational Prize, we aim to recognize and celebrate the scientists whose discoveries have crossed that crucial bridge - from insight to impact - and to highlight the importance of translational research in advancing human health.”

The Prize will be administered by Royalty Pharma and selected by an independent international committee of leading scientists and industry experts. The committee will be chaired by Sir Gregory Winter, Nobel Laureate in Chemistry and pioneer of antibody engineering whose work has led to multiple life‑saving therapies.

“The Royalty Pharma Translational Prize will help create a culture of translation in academia, encourage other people into the area and facilitate the creation of new medicines. By recognizing scientists whose work has demonstrably improved patient care, the Royalty Pharma Translational Prize underscores the essential role that translational research plays in turning promising discoveries into medicines.” said Sir Gregory Winter.

The Prize will be presented annually, with nominations opening in summer 2026. The first laureate will be recognized in spring 2027 at the Accelerating Bio‑Innovation (ABI) conference.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Biogen’s Tysabri and Spinraza, Roche’s Evrysdi, Astellas and Pfizer’s Xtandi, Johnson & Johnson’s Tremfya, AbbVie and Johnson & Johnson’s Imbruvica, Servier’s Voranigo, Gilead’s Trodelvy, Amgen’s Imdelltra and Alnylam’s Amvuttra, among others, and 19 development-stage product candidates. For more information, visit www.royaltypharma.com.

About the Royalty Pharma Translational Prize

The Prize honors scientific breakthroughs that bridge the gap between fundamental discovery and the development of new medicines that improve and extend patients’ lives. It is awarded annually to one or more established scientists whose work has translated unique scientific insights into medicines with significant impact, particularly contributions not yet recognized by the field’s most prominent awards. For more information, visit www.rptranslationalprize.com.

About Accelerating Bio-Innovation

The Accelerating Bio-Innovation conference series was created by Royalty Pharma as a forum that bridges the worlds of academia, industry, and finance to gain new insights and inspire collaborations that will lead to new medicines. Alternating between the University of Cambridge UK and the Massachusetts Institute of Technology, the invitation-only ABI conference brings together life-science business leaders, renowned scientists, visionary entrepreneurs, and finance innovators. At the heart of each ABI conference is a curated program featuring world-class speakers, engaging social events, and high-impact networking opportunities, all designed to inspire dialogue, foster connections, and drive innovation in life sciences. For more information, visit www.abiconference.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
[email protected]

Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%Net cash provided by operating activities of $718 millionRaised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million to $3,450 million NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts.

“Royalty Pharma has delivered a strong start to 2026 across multiple dimensions. We grew Royalty Receipts by 13% and announced up to $1.25 billion of royalty transactions in the first quarter,” said Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board. “Importantly, we continue to innovate our business and are very excited by the emergence of a significant opportunity in R&D co-funding with global biopharma companies. Our transactions this year included two such agreements - with Johnson & Johnson and Teva - underscoring the growing demand for this novel funding modality. We were also delighted by positive clinical and regulatory developments across our portfolio, notably the unprecedented overall survival benefit for daraxonrasib in pancreatic cancer. Lastly, we took major steps to strengthen our capabilities in the Asia-Pacific region, Partnering and AI with the addition of key leaders to our team. As a result, we are incredibly well positioned as a premier capital allocator in life sciences to deliver consistent, compounding growth.”

Double-digit growth in Royalty Receipts and Portfolio Receipts

Royalty Receipts grew 13% to $887 million in the first quarter of 2026 driven by Tremfya, Voranigo and Evrysdi.Portfolio Receipts increased by 10% to $925 million. Strong transaction activity

Acquired three royalties for $1.25 billion in announced value; Capital Deployment of $528 million in the first quarter.R&D co-funding collaborations in immunology announced with Johnson & Johnson on JNJ-4804 and Teva on TEV-’408. Positive clinical and regulatory updates across royalty portfolio

Positive Phase 3 results for Revolution Medicines’ daraxonrasib in pancreatic cancer and Cytokinetics’ Myqorzo in non-obstructive hypertrophic cardiomyopathy.Denali’s Avlayah (tividenofusp alfa) approved by FDA (Hunter syndrome); Nuvalent’s neladalkib (lung cancer) New Drug Application submitted to FDA. Raising financial guidance for full year 2026 (excludes contribution from future transactions)

Royalty Pharma now expects 2026 Portfolio Receipts to be between $3,325 million and $3,450 million (previously $3,275 million to $3,425 million), representing expected Royalty Receipts growth of 4% to 8%. Financial & Liquidity Summary

 Three Months Ended March 31,($ and shares in millions; unaudited)20262025ChangePortfolio Receipts92583910%Net cash provided by operating activities71859620%Adjusted EBITDA (non-GAAP)*88973821%Portfolio Cash Flow (non-GAAP)*72261118%Weighted average Class A ordinary shares outstanding - diluted557578(4)% *See “Liquidity and Capital Resources” section. Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures calculated in accordance with the credit agreement.

2026 Financial Outlook

Royalty Pharma has provided guidance for full year 2026, excluding new transactions and borrowings announced after the date of this release, as follows:

 Provided May 6, 2026PreviousPortfolio Receipts$3,325 million to $3,450 million$3,275 million to $3,425 millionPayments for operating and professional costs5.5% to 6.5% of Portfolio Receipts5.5% to 6.5% of Portfolio ReceiptsInterest paid$350 million to $360 million$350 million to $360 million Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. The above Portfolio Receipts guidance provided on May 6, 2026 includes expected Royalty Receipts growth of 4% to 8% in 2026.

Royalty Pharma’s full year 2026 guidance reflects an estimated foreign exchange impact of approximately +1% to Portfolio Receipts, assuming current foreign exchange rates prevail for the rest of 2026.

Payments for operating and professional costs in 2026 are expected to decrease as a percentage of Portfolio Receipts, compared to 8.9% in 2025, primarily due to extinguishment of the management fee following the completion of the internalization transaction on May 16, 2025.

Total interest paid is based on the semi-annual interest payment schedule of Royalty Pharma’s existing notes and the quarterly interest payment schedule for the term loan assumed as part of the internalization transaction. In 2026, Royalty Pharma anticipates interest paid to be approximately $350 million to $360 million.(5) Interest paid in the third quarter of 2026 is anticipated to be approximately $175 million. De minimis amounts are anticipated in the second and fourth quarters of 2026. These projections assume no additional debt financing in 2026, including no drawdown on the revolving credit facility. In the first quarter of 2026, Royalty Pharma collected interest of $6 million on its cash and cash equivalents, which partially offset interest paid.

Royalty Pharma today provides this guidance based on its most up-to-date view of its prospects. This guidance assumes no major unforeseen adverse events or changes in foreign exchange rates and excludes the contributions from transactions announced subsequent to the date of this press release.

Portfolio Receipts Highlights

 Three Months Ended March 31,($ in millions; unaudited)20262025ChangeProducts:Marketers:Therapeutic Area:   Cystic fibrosis franchiseVertexRare disease2532501%TrelegyGSKRespiratory988515%EvrysdiRocheRare disease805351%TremfyaJohnson & JohnsonImmunology643679%TysabriBiogenNeuroscience5961(3)%XtandiPfizer, AstellasOncology5152(3)%VoranigoServierOncology4720140%ImbruvicaAbbVie, Johnson & JohnsonOncology3846(17)%Cabometyx/CometriqExelixis, Ipsen, TakedaOncology23219%PromactaNovartisHematology1744(61)%ImdelltraAmgenOncology17—n/aTrodelvyGileadOncology13137%SpinrazaBiogenRare disease1213(9)%AmvuttraAlnylamRare disease8—n/aOther products(6)1089612%Royalty Receipts88778813%Milestones and other contractual receipts3851(25)%Portfolio Receipts92583910% Amounts shown in the table may not add due to rounding.

Royalty Receipts was $887 million in the first quarter of 2026, an increase of 13% compared to $788 million in the first quarter of 2025. The increase was primarily driven by Tremfya, Voranigo and Evrysdi, partially offset by a decline from Promacta due to U.S. generic competition. Royalty Receipts from Evrysdi included the benefit of the additional royalties acquired in December 2025.

Portfolio Receipts was $925 million in the first quarter of 2026, an increase of 10% compared to $839 million in the first quarter of 2025, primarily driven by the same Royalty Receipts increases noted above, partially offset by lower Milestones and other contractual receipts.

Liquidity and Capital Resources

Royalty Pharma’s liquidity and capital resources are summarized below:

As of March 31, 2026, Royalty Pharma had cash and cash equivalents of $586 million and total debt with principal value of $9.2 billion.

In the first quarter of 2026, Royalty Pharma paid a quarterly dividend of $0.235 per share, equating to $136 million in dividends and distributions.

In January 2025, Royalty Pharma announced a share repurchase program under which it may repurchase up to $3.0 billion of its Class A ordinary shares. Royalty Pharma repurchased approximately 1.1 million Class A ordinary shares for $50 million in the first quarter of 2026. The weighted-average number of diluted Class A ordinary shares outstanding for the first quarter of 2026 was 557 million, a decline of 4% as compared to 578 million for the first quarter of 2025.

Liquidity Summary

 Three Months Ended March 31,($ in millions; unaudited)2026 2025 Portfolio Receipts925 839 Payments for operating and professional costs(36)(102)Adjusted EBITDA (non-GAAP)889 738 Interest paid, net(167)(127)Portfolio Cash Flow (non-GAAP)722 611  Amounts may not add due to rounding.

Adjusted EBITDA (non-GAAP) was $889 million in the first quarter of 2026. Adjusted EBITDA is calculated as Portfolio Receipts minus payments for operating and professional costs.Portfolio Cash Flow (non-GAAP) was $722 million in the first quarter of 2026. Portfolio Cash Flow is calculated as Adjusted EBITDA minus interest paid or received, net. This measure reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases, or utilized for other discretionary investments. Refer to Table 4 for Royalty Pharma’s reconciliation of each non-GAAP measure to the most directly comparable GAAP financial measure, net cash provided by operating activities.

Capital Deployment reflects cash payments during the period for new and previously announced transactions. Capital Deployment was $528 million in the first quarter of 2026, consisting primarily of upfront payments for the Ziihera (see ‘Royalty Transactions’) and Avlayah (formerly known as tividenofusp alfa) transactions and a milestone payment related to Trelegy.

The table below details Capital Deployment by category:

Capital Deployment

 Three Months Ended March 31,($ in millions; unaudited)2026 2025 Acquisitions of financial royalty assets(452)(1)Development-stage funding payments(26)(51)Milestone payments(50)(50)Contributions from legacy non-controlling interests - R&D— 0 Capital Deployment(528)(101) Amounts may not add due to rounding.

Royalty Transactions

During the first quarter of 2026, Royalty Pharma announced new transactions of up to $1.25 billion, which reflects the entire amount of potential capital committed for new transactions, including potential future milestones.

Recent transactions include:

In March 2026, Royalty Pharma entered into an R&D co-funding arrangement with Johnson & Johnson to provide $500 million over two years for the development of JNJ‑4804, an investigational medicine for autoimmune diseases.In March 2026, Royalty Pharma acquired a royalty interest in Ziihera from Zymeworks Inc. for $250 million. Ziihera, which is marketed by Jazz Pharmaceuticals and BeOne Medicines, is approved for human epidermal growth factor receptor 2 (HER2)-positive metastatic biliary tract cancer and is in development for HER2-positive gastric cancer.In January 2026, Royalty Pharma announced a funding agreement with Teva Pharmaceuticals for TEV-’408 for up to $500 million. The agreement includes up to $75 million to co-fund a Phase 2b study for vitiligo targeted for 2026. Based on the results of this study, Royalty Pharma has the option to provide up to an additional $425 million to co-fund the Phase 3 development program. The information in this section should be read together with Royalty Pharma’s reports and documents filed with the SEC at www.sec.gov and the reader is also encouraged to review all other press releases and information available in the Investors section of Royalty Pharma’s website at www.royaltypharma.com.

Key Developments Relating to the Portfolio

The key developments related to Royalty Pharma’s royalty interests are discussed below based on disclosures from the marketers of the products.

MyqorzoIn May 2026, Cytokinetics announced positive topline results from ACACIA-HCM, the pivotal phase 3 clinical trial of Myqorzo in patients with non-obstructive hypertrophic cardiomyopathy. ACACIA-HCM met both dual primary endpoints, demonstrating statistically significant improvements from baseline to week 36 compared to placebo.In February 2026, Cytokinetics announced that the European Commission (EC) approved Myqorzo for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients.

ZiiheraIn April 2026, Jazz Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) accepted for filing, with Priority Review, a supplemental Biologics License Application for Ziihera in combination regimens for the first line treatment of adult patients with HER2-positive metastatic gastroesophageal adenocarcinoma. The FDA has set a Prescription Drug User Fee Act target action date of August 25, 2026.daraxonrasibIn April 2026, Revolution Medicines announced positive Phase 3 results from the RASolute 302 trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic cancer. Based on these results, Revolution Medicines intends to submit the data to global regulatory authorities, including the FDA, as part of a future New Drug Application (NDA) under the Commissioner’s National Priority Voucher program.neladalkibIn April 2026, Nuvalent announced the submission of an NDA to the FDA for neladalkib, an investigational anaplastic lymphoma kinase (ALK)‑selective inhibitor, for tyrosine kinase inhibitor pre‑treated advanced ALK‑positive non-small cell lung cancer.SpinrazaIn March 2026, Biogen announced that the FDA approved the high dose regimen of Spinraza for spinal muscular atrophy (SMA).In January 2026, Biogen announced that the EC granted marketing authorization for a high dose regimen of Spinraza for SMA.

litifilimabIn March 2026, Biogen reported positive Phase 2 results from the AMETHYST Phase 2/3 study (Part A) of litifilimab in cutaneous lupus erythematosus (CLE), demonstrating reductions in skin disease activity through week 24.In January 2026, Biogen announced that the FDA granted Breakthrough Therapy Designation for litifilimab for the treatment of CLE.

AvlayahIn March 2026, Denali Therapeutics announced that the FDA granted accelerated approval of Avlayah (tividenofusp alfa) for the treatment of Hunter syndrome. Avlayah is the first FDA-approved biologic specifically designed to cross the blood-brain barrier and reach the whole body, including the brain.TazverikIn March 2026, Ipsen announced that it was voluntarily withdrawing Tazverik from all Ipsen markets based on emerging data from the ongoing Phase Ib/III SYMPHONY-1 trial. In addition, Eisai announced plans to discontinue sales of Tazverik in Japan. In the first quarter of 2026, Royalty Pharma recorded $69 million of non-cash impairment charges related to Tazverik.ampreloxetineIn March 2026, Theravance Biopharma reported that the Phase 3 CYPRESS study evaluating ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension due to multiple system atrophy did not meet the primary endpoint. As a result, Theravance will wind down the ampreloxetine program.TEV-’749In February 2026, Teva Pharmaceuticals announced that the FDA accepted the NDA for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults.pelabresibIn January 2026, Novartis announced plans to submit a European Union regulatory filing for pelabresib in 2026, and that it would begin a new Phase 3 study in the United States, China and Japan.obexelimabIn January 2026, Zenas BioPharma announced positive results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-related disease (IgG4-RD), which met the primary endpoint demonstrating a clinically meaningful and highly statistically significant reduction in risk of IgG4-RD flare. Zenas anticipates submitting a Biologics License Application in Q2 2026 and a Marketing Authorization Application to the European Medicines Agency in the second half of 2026. Financial Results Call

Royalty Pharma will host a conference call and simultaneous webcast to discuss its first quarter 2026 results today at 8:00 a.m., Eastern Time. Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Biogen’s Tysabri and Spinraza, Roche’s Evrysdi, Astellas and Pfizer’s Xtandi, Johnson & Johnson’s Tremfya, AbbVie and Johnson & Johnson’s Imbruvica, Servier’s Voranigo, Gilead’s Trodelvy, Amgen’s Imdelltra and Alnylam’s Amvuttra, among others, and 19 development-stage product candidates.

Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities, market growth and plans for capital deployment, plus the benefits of the internalization transaction, including expected accretion, enhanced alignment with shareholders, increased investment returns, expectations regarding management continuity, transparency and governance, and the benefits of simplification to its structure. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.

For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR on the SEC’s website at www.sec.gov.

Portfolio Receipts

Portfolio Receipts is a key performance metric that represents Royalty Pharma’s ability to generate cash from Royalty Pharma’s portfolio investments, the primary source of capital that is deployed to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty Receipts and Milestones and other contractual receipts. Royalty Receipts includes variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma.

Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to legacy non-controlling interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include royalty receipts and milestones and other contractual receipts that were received on an accelerated basis under the terms of the agreement governing the receipt or payment. Portfolio Receipts also does not include proceeds from equity securities or proceeds from purchases and sales of marketable securities, both of which are not central to Royalty Pharma’s fundamental business strategy. 2025 Portfolio Receipts does not include the $511 million of proceeds from the sale of the MorphoSys Development Funding Bonds, as the transaction was treated as an asset sale.

Portfolio Receipts is calculated as the sum of the following line items from Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees less Distributions to legacy non-controlling interests - Portfolio Receipts, which represent contractual distributions of Royalty Receipts, milestones and other contractual receipts to the Legacy Investors Partnerships.

Use of Non-GAAP Measures

Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures that exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. Management believes that Adjusted EBITDA and Portfolio Cash Flow are important non-GAAP measures used to analyze liquidity because they are key components of certain material covenants contained within Royalty Pharma’s credit agreement. Royalty Pharma cautions readers that amounts presented in accordance with the definitions of Adjusted EBITDA and Portfolio Cash Flow may not be the same as similar measures used by other companies or analysts. These non-GAAP liquidity measures have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of Royalty Pharma’s results as reported under GAAP.

The definitions of Adjusted EBITDA and Portfolio Cash Flow used by Royalty Pharma are the same as the definitions in the credit agreement. Noncompliance with the interest coverage ratio, leverage ratio and Portfolio Cash Flow ratio covenants under the credit agreement could result in lenders requiring the company to immediately repay all amounts borrowed. If Royalty Pharma cannot satisfy these covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA and Portfolio Cash Flow are critical to the assessment of Royalty Pharma’s liquidity.

Adjusted EBITDA and Portfolio Cash Flow are used by management as key liquidity measures in the evaluation of the company’s ability to generate cash from operations. Management uses Adjusted EBITDA and Portfolio Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, debt repayments, dividends and other discretionary investments. Further, these non-GAAP liquidity measures help management, the audit committee and investors evaluate the company’s ability to generate liquidity from operating activities.

The company has provided reconciliations of these non-GAAP liquidity measures to the most directly comparable GAAP financial measure, being net cash provided by operating activities in Table 4.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
[email protected]

Royalty Pharma plc
Condensed Consolidated Statements of Operations(8)(unaudited)
Table 1   Three Months Ended March 31,($ in millions)2026
2025
Income and other revenues  Income from financial royalty assets595 539 Other royalty income and revenues36 29 Total income and other revenues631 568 Operating (income)/expense  Provision for changes in expected cash flows from financial royalty assets(197)(127)Provision for credit losses on unfunded commitments(4)— Research and development funding expense40 51 General and administrative expenses (includes 122 and 1 of share-based compensation expense for the three months ended March 31, 2026 and 2025, respectively)159 111 Financial royalty asset impairment69 — Total operating expense, net68 34 Operating income563 534 Other (income)/expense  Equity in earnings of equity method investees(22)(6)Interest expense94 65 Other expense, net23 41 Total other expense, net95 100 Consolidated net income before tax468 434 Income tax expense— — Consolidated net income468 434 Net income attributable to non-controlling interests174 195 Net income attributable to Royalty Pharma plc295 239  Amounts may not add due to rounding.

Royalty Pharma plc
Selected Balance Sheet Data (unaudited)
Table 2   ($ in millions)As of March 31, 2026As of December 31, 2025Cash and cash equivalents586619Total current and non-current financial royalty assets, net17,32217,063Total assets19,81519,621Current portion of long-term debt380380Long-term debt, net of current portion8,5768,571Total liabilities9,8799,906Total shareholders’ equity9,9379,715 Royalty Pharma plc
Condensed Consolidated Statements of Cash Flows (unaudited)
Table 3   Three Months Ended March 31,($ in millions)2026 2025 Cash flows from operating activities:  Cash collections from financial royalty assets916 830 Cash collections from intangible royalty assets4 0 Other royalty cash collections34 32 Distributions from equity method investees4 13 Interest received6 12 Development-stage funding payments(26)(51)Payments for operating and professional costs(36)(102)Payments for Employee EPAs(10)— Interest paid(174)(139)Net cash provided by operating activities718 596 Cash flows from investing activities:  Distributions from equity method investees42 36 Purchases of equity securities(23)(4)Proceeds from equity securities0 — Proceeds from available for sale debt securities4 13 Proceeds from sales of available for sale debt securities— 511 Acquisitions of financial royalty assets(452)(1)Milestone payments(50)(50)Net cash (used in)/provided by investing activities(478)504 Cash flows from financing activities:  Distributions to legacy non-controlling interests - Portfolio Receipts(78)(85)Distributions to continuing non-controlling interests(40)(54)Dividends to shareholders(104)(95)Repurchases of Class A ordinary shares(50)(709)Contributions from legacy non-controlling interests - R&D— 0 Contributions from non-controlling interests - other— 1 Other(0)— Net cash used in financing activities(273)(941)Net change in cash and cash equivalents(32)159 Cash and cash equivalents, beginning of period619 929 Cash and cash equivalents, end of period586 1,088  EPAs: Equity Performance Awards. Amounts may not add due to rounding.

Royalty Pharma plc
GAAP to Non-GAAP Reconciliation (unaudited)
Table 4   Three Months Ended March 31,($ in millions)2026 2025 Net cash provided by operating activities (GAAP)718 596 Adjustments:  Proceeds from available for sale debt securities(7)4 13 Distributions from equity method investees(7)42 36 Interest paid, net(7)167 127 Development-stage funding payments26 51 Distributions to legacy non-controlling interests - Portfolio Receipts(7)(78)(85)Payments for Employee EPAs10 — Adjusted EBITDA (non-GAAP)889 738 Interest paid, net(7)(167)(127)Portfolio Cash Flow (non-GAAP)722 611  EPAs: Equity Performance Awards. Amounts may not add due to rounding.

Royalty Pharma plc
Description of Approved Indications for Select Portfolio Therapies
Table 5
Cystic fibrosis franchise
Cystic fibrosisTrelegyChronic obstructive pulmonary disease and asthmaEvrysdiSpinal muscular atrophyTremfyaPlaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s diseaseTysabriRelapsing forms of multiple sclerosisXtandiProstate cancerVoranigoLow-grade gliomaImbruvicaHematological malignancies and chronic graft versus host diseaseCabometyx/CometriqKidney, liver and thyroid cancerPromactaChronic immune thrombocytopenia purpura and aplastic anemiaImdelltraSmall cell lung cancerTrodelvyBreast cancerSpinrazaSpinal muscular atrophyAmvuttraTransthyretin amyloidosis   Notes
 (1)Portfolio Receipts is defined above in the section entitled “Portfolio Receipts.”(2)  Adjusted EBITDA is defined under the credit agreement as Portfolio Receipts minus payments for operating and professional costs. Operating and professional costs reflect Payments for operating and professional costs from the GAAP condensed consolidated statements of cash flows. See GAAP to Non-GAAP reconciliation in Table 4.(3)Portfolio Cash Flow is defined under the credit agreement as Adjusted EBITDA minus interest paid or received, net. See GAAP to Non-GAAP reconciliation in Table 4. Portfolio Cash Flow reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases or utilized for other discretionary investments.(4)Capital Deployment is calculated as the summation of the following line items from Royalty Pharma’s GAAP condensed consolidated statements of cash flows: Investments in equity method investees, Purchases of available for sale debt securities, Acquisitions of financial royalty assets, Acquisitions of other financial assets, Milestone payments, Development-stage funding payments less Contributions from legacy non-controlling interests - R&D.(5)The term loan that Royalty Pharma assumed as part of the Internalization has a Secured Overnight Financing Rate (SOFR) based variable interest rate. Royalty Pharma estimated the related interest payment for 2026 based on the forward curve as of April 29, 2026.(6)Other products primarily include Royalty Receipts on the following products: Crysvita, Emgality, Erleada, Farxiga/Onglyza, IDHIFA, Niktimvo, Nurtec ODT, Orladeyo, Skytrofa, Soliqua, Yorvipath and distributions from the Legacy SLP Interest, which is presented as Distributions from equity method investees on the GAAP condensed consolidated statements of cash flows.(7)The table below shows the line item for each adjustment and the direct location for such line item on the GAAP condensed consolidated statements of cash flows. Reconciling AdjustmentStatements of Cash Flows ClassificationInterest paid, netOperating activities (Interest paid less Interest received)Distributions from equity method investeesInvesting activitiesProceeds from available for sale debt securitiesInvesting activitiesDistributions to legacy non-controlling interests - Portfolio ReceiptsFinancing activities (8)The condensed consolidated statement of operations for 2025 has been recast to reflect the adoption of ASU 2025-07 by removing the losses previously recognized on derivative.

Have you been paying attention to shares of Royalty Pharma (RPRX - Free Report) ? Shares have been on the move with the stock up 7.6% over the past month. The stock hit a new 52-week high of $50.82 in the previous session. Royalty Pharma has gained 30.5% since the start of the year compared to the -7.3% gain for the Zacks Medical sector and the -1.6% return for the Zacks Medical - Biomedical and Genetics industry.

What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on May 6, 2026, Royalty Pharma reported EPS of $1.3 versus consensus estimate of $1.22 while it beat the consensus revenue estimate by 5.95%.

For the current fiscal year, Royalty Pharma is expected to post earnings of $5.08 per share on $3.45 in revenues. This represents a 5.18% change in EPS on a 5.95% change in revenues. For the next fiscal year, the company is expected to earn $5.41 per share on $3.63 in revenues. This represents a year-over-year change of 6.35% and 5.36%, respectively.

Valuation MetricsThough Royalty Pharma has recently hit a 52-week high, what is next for Royalty Pharma? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.

On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.

Royalty Pharma has a Value Score of B. The stock's Growth and Momentum Scores are C and C, respectively, giving the company a VGM Score of B.

In terms of its value breakdown, the stock currently trades at 9.9X current fiscal year EPS estimates, which is not in-line with the peer industry average of 21.7X. On a trailing cash flow basis, the stock currently trades at 10.6X versus its peer group's average of 13.9X. Additionally, the stock has a PEG ratio of 3.22. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.

Zacks RankWe also need to consider the stock's Zacks Rank, as this is even more important than the company's VGM Score. Fortunately, Royalty Pharma currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.

Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Royalty Pharma passes the test. Thus, it seems as though Royalty Pharma shares could have potential in the weeks and months to come.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX - Free Report) and Amgen (AMGN - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.

Royalty Pharma has a Zacks Rank of #2 (Buy), while Amgen has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that RPRX likely has seen a stronger improvement to its earnings outlook than AMGN has recently. But this is only part of the picture for value investors.

Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.

The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.

RPRX currently has a forward P/E ratio of 9.92, while AMGN has a forward P/E of 14.84. We also note that RPRX has a PEG ratio of 3.22. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. AMGN currently has a PEG ratio of 3.35.

Another notable valuation metric for RPRX is its P/B ratio of 3. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, AMGN has a P/B of 19.35.

These metrics, and several others, help RPRX earn a Value grade of B, while AMGN has been given a Value grade of C.

RPRX is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that RPRX is likely the superior value option right now.

Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Paysafe Limited (NYSE: PSFE) between March 4, 2025 and November 12, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.

So What: If you purchased Paysafe securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Paysafe class action, go to https://rosenlegal.com/submit-form/?case_id=2745 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Paysafe's ecommerce business had significant exposure to a single high risk client; (2) as a result, Paysafe's credit loss reserves and/or write-offs were understated; (3) Paysafe had an undisclosed issue with higher risk Merchant Category Codes, making its client services difficult to bank; (4) the foregoing issues were likely to have a material negative impact on Paysafe's revenue growth and overall revenue mix; (5) as a result, Paysafe was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (6) as a result of the foregoing, defendants' positive statements about Paysafe's  business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Paysafe class action, go to https://rosenlegal.com/submit-form/?case_id=2745 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Paysafe Limited (NYSE: PSFE).

Shareholders who purchased shares of PSFE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:
https://securitiesclasslaw.com/securities/paysafe-limited-loss-submission-form/?id=185254&from=4 

CLASS PERIOD: March 4, 2025 to November 12, 2025

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Paysafe's ecommerce business had significant exposure to a single high risk client; (2) as a result, the Company's credit loss reserves and/or write-offs were understated; (3) Paysafe had an undisclosed issue with higher risk merchant category codes, making its client services difficult to bank; (4) foregoing issues were likely to have a material negative impact on the Company's revenue growth and overall revenue mix; (5) as a result, Paysafe was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (6) that, as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

DEADLINE: April 7, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/paysafe-limited-loss-submission-form/?id=185254&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of PSFE during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 7, 2026. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

SOURCE The Gross Law Firm

By PYMNTS  |  April 7, 2026

 | 

Global payments platform Paysafe now enables iGaming operators and daily fantasy sports brands in the U.S. market to accept crypto payments.

The company’s new Pay with Crypto payment method lets iGaming brands’ customers fund their player accounts with stablecoins or cryptocurrency, where permitted, and then converts that crypto deposit to U.S. dollars to allow play, Paysafe said in a Tuesday (April 7) press release.

The solution is powered by global crypto payments and stablecoin infrastructure firm MoonPay, according to the release.

For operators, Pay with Crypto offers a choice of settling payment almost instantly in stablecoins in their business’s crypto wallet or settling in U.S. dollars or any major fiat currency, per the release.

The use of cryptocurrency is evolving from investment to payments, Zak Cutler, president of global gaming at Paysafe, said in the release.

“Against this backdrop, we’re delighted to unveil Pay with Crypto, a forward-thinking solution that strongly positions U.S. operators for their customers’ changing transactional preferences — the future of how they pay when they play,” Cutler said.

Advertisement: Scroll to Continue

MoonPay Founder and CEO Ivan Soto-Wright said in the release that crypto rails make payments faster and more efficient.

“People shouldn’t have to convert their digital assets just to make a purchase — they want to use what they already have,” Soto-Wright said. “Paysafe brings that experience to more people through trusted, regulated platforms.”

Pay with Crypto joins several other payment methods enabled by Paysafe Gateway, which was developed specifically for iGaming. Paysafe Gateway also enables card payments, the Skrill digital wallet, the PaysafeCash eCash solution, a Pay by Bank product and more than 30 local payment methods, according to the release.

Payments increasingly sit at the center of a makeover of the sector in which sportsbooks and online gaming platforms compete for player loyalty, Cutler told PYMNTS in an interview posted in February 2025.

“Payments aren’t just a back-end function — they’re a strategic growth driver,” Cutler said. “The more seamless the process, the higher the conversion, retention and overall user satisfaction. That’s where the industry is headed.”

Paysafe reported in March that volumes in iGaming during the U.S. football season reached record levels, underscoring steady demand in entertainment-driven categories.

In 2025, the company’s North American iGaming business saw 50% processing revenue growth, Paysafe said in a March 3 earnings report.

, /PRNewswire/ -- MoonPay, the global leader in crypto payments and stablecoin infrastructure, is now powering crypto payments inside Paysafe (NYSE: PSFE), a global payments platform that processed $167 billion in transactions in 2025. The integration embeds stablecoin rails directly into Paysafe's platform, giving merchants crypto payment capability alongside cards, digital wallets, eCash, bank transfers, and local payment rails.

The first product to launch from the partnership is Pay with Crypto, which allows brands' customers to use their preferred stablecoin or cryptocurrency to fund their accounts, where permitted. Whether a customer wants to fund an account using USD Coin (USDC), another stablecoin, or any major cryptocurrency, Paysafe's new payment option for operators' cashiers enables their crypto deposit to be rapidly converted to U.S. dollars. The solution supports e-commerce, financial services, retail, and iGaming and daily fantasy sports operators, among other verticals.

Ivan Soto-Wright, Founder and CEO of MoonPay, commented: "Crypto rails are making payments faster and cheaper, and our job is to close the gap between this technology and real-world utility."

Crypto as a Payments Rail

The integration reflects a broader shift in how stablecoin infrastructure scales. Rather than going direct-to-consumer, MoonPay is powering the crypto capability of an established payment processor, embedding stablecoin rails into traditional checkout flows. For merchants, that means gaining crypto payment functionality through Paysafe without requiring a separate integration.

Zak Cutler, President of Global Gaming at Paysafe, said: "Galvanized by the growing popularity of stablecoins, cryptocurrency is evolving in the U.S. from an investment asset into a unit of value for payments, and we're seeing this shift gather pace in the country's online gaming market. Against this backdrop, we're delighted to unveil Pay with Crypto, a forward-thinking solution that strongly positions U.S. operators for their customers' changing transactional preferences – the future of how they pay when they play."

How Pay with Crypto Works

After selecting Pay with Crypto and their preferred stablecoin or cryptocurrency, users simply connect their crypto or custodial wallet to fund the deposit, with the MoonPay Commerce Checkouts technology also supporting transactions via QR code using users' phones. Once transactions have been verified, Pay with Crypto instantly converts crypto deposits into U.S. dollars to fund the user's account.

For a daily fantasy sports operator, that means a player can fund their account with a stablecoin in seconds, expanding available deposit options without any additional integration work.

The flexibility embedded in the Pay with Crypto solution also extends to operators, which can choose to settle payments almost instantly in stablecoins in their business's crypto wallet, or settle in U.S. dollars or any major fiat currency through MoonPay's Virtual Accounts powered by Iron.

Disclaimer
Neither Paysafe nor any of its affiliates endorse or promote any form of wagering or gambling. Please note that all forms of gambling and betting (online and otherwise) carry with them inherent financial risk and risk of financial loss. Any gambling or betting activities should be exercised responsibly and with moderation in compliance with all applicable laws and regulations.

About Paysafe
Paysafe is a global payments platform powering the experience economy, with a strong focus on the iGaming, video gaming, e-commerce, online trading, retail, travel and hospitality sectors. With 30 years of expertise in payment technology, Paysafe helps businesses and consumers lift every experience through seamless, secure payment solutions, including card payments, digital wallets such as Skrill, eCash solutions like PaysafeCard, and a suite of local payment methods. With approximately 2,800 employees across 12 countries and annualized transactional volume of $167 billion in 2025, Paysafe connects people and businesses worldwide through innovative digital payment experiences. Further information is available at www.paysafe.com

About MoonPay
Founded in 2019, MoonPay is a global financial technology company that helps businesses and consumers move value across fiat and digital assets. MoonPay has more than 30 million customers across 180 countries and supports more than 500 enterprise customers spanning crypto and fintech.

MoonPay powers ramps, trading, commerce, and stablecoin infrastructure, connecting traditional payment rails with blockchains. MoonPay maintains a broad regulatory footprint, including a New York BitLicense, a New York Limited Purpose Trust Charter, and money transmitter licenses across the United States, as well as MiCA authorization in the EU.

MoonPay is how the world moves value. 

For media enquiries, contact:
[email protected]

SOURCE MoonPay

-

Paysafe’s consumer offering expands across 18 European markets, enabling a seamless journey from cash solutions to full-service digital wallet with an IBAN-enabled account and debit card

LONDON--(BUSINESS WIRE)--Paysafe (NYSE: PSFE), a global payments platform, today introduces PaysafeWallet, the digital wallet designed to support everyday financial management for cash and digital-preferred consumers in the experience economy.

PaysafeWallet has been fully rolled out across the PaysafeCard app, website, and customer-facing marketing in all live markets, creating one clear and unified value proposition.

Share PaysafeWallet enables customers to send, receive, spend, and withdraw money, supported by a dedicated IBAN-enabled personal payment account and debit card. This solution represents the evolution of PaysafeCard’s Account & Card into a full-service digital wallet. PaysafeWallet has been fully rolled out across the PaysafeCard app, website, and customer-facing marketing in all live markets, creating one clear and unified value proposition.

PaysafeWallet is now live across 18 European markets: Germany, France, Greece, Spain, Italy, Austria, the Netherlands, Slovakia, Belgium, Portugal, Ireland, Slovenia, Finland, Cyprus, Latvia, Lithuania, Luxembourg, and Malta.

For existing users, nothing changes. More than 600,000 customers will continue to access cash deposits and their IBAN‑based account and debit card with uninterrupted service and functionality. At the same time, PaysafeWallet is expanding into new countries where PaysafeCard is already a very popular online payment method.

“PaysafeWallet is a core consumer product and a brand that carries the Paysafe name and represents where we are headed,” said Bob Legters, Chief Product Officer at Paysafe. “It connects cash‑based consumers to a modern digital wallet experience, combining everyday usability with the financial services they need to participate fully in the experience economy.”

PaysafeWallet builds on strong early momentum. Initially launched in select European markets to bring wallet capabilities to cash and digital consumers, the platform quickly expanded across multiple markets. Today, PaysafeWallet plays a central role in Paysafe’s strategy to create a connected consumer journey, enabling customers to move seamlessly from cash solutions to full‑service digital wallets.

About Paysafe

Paysafe is a global payments platform powering the experience economy, with a strong focus on the iGaming, video gaming, e-commerce, online trading, retail, travel and hospitality sectors. With 30 years of expertise in payment technology, Paysafe helps businesses and consumers lift every experience through seamless, secure payment solutions, including card payments, digital wallets such as Skrill, eCash solutions like PaysafeCard, and a suite of local payment methods. With approximately 2,800 employees across 12 countries and annualized transactional volume of $167 billion in 2025, Paysafe connects people and businesses worldwide through innovative digital payment experiences. Further information is available at www.paysafe.com

More News From Paysafe

Back to Newsroom

-

LONDON--(BUSINESS WIRE)--Paysafe Limited (NYSE: PSFE) today announced financial results for the first quarter of 2026 that will be furnished with the Securities and Exchange Commission on a Form 6-K and available on its Investor Relations website at https://ir.paysafe.com/financial-info-and-filings/financial-results

Webcast and Conference Call

Paysafe will host a live webcast to discuss the results today at 8:30 a.m. (ET). The webcast and supplemental information can be accessed on the investor relations section of the Paysafe website at ir.paysafe.com. An archive will be available after the conclusion of the live event and will remain available via the same link for one year.

About Paysafe

Paysafe is a global payments platform powering the experience economy, with a strong focus on the iGaming, video gaming, e-commerce, online trading, retail, travel and hospitality sectors. With 30 years of expertise in payment technology, Paysafe helps businesses and consumers lift every experience through seamless, secure payment solutions, including card payments, digital wallets such as Skrill, eCash solutions like PaysafeCard, and a suite of local payment methods. With approximately 2,800 employees across 12 countries and annualized transactional volume of $167 billion in 2025, Paysafe connects people and businesses worldwide through innovative digital payment experiences. Further information is available at www.paysafe.com.

More News From Paysafe Limited

Back to Newsroom

Paysafe Limited (PSFE) Q1 2026 Earnings Call Transcript

LONDON--(BUSINESS WIRE)--Paysafe Limited (NYSE: PSFE), a global payments platform, today announced that Chief Financial Officer, John Crawford, will participate in a fireside chat at the RBC Capital Markets Global Financial Technology Conference on Tuesday, June 9, 2026 in New York, NY. The discussion will begin at 3:30 pm ET. Management will also participate in investor meetings throughout the day.

A live webcast of the fireside chat will be available on the Paysafe Investor Relations website at ir.paysafe.com under the “Events” section and archived for a limited time.

About Paysafe

Paysafe is a global payments platform powering the experience economy, with a strong focus on the iGaming, video gaming, e-commerce, online trading, retail, travel and hospitality sectors. With 30 years of expertise in payment technology, Paysafe helps businesses and consumers lift every experience through seamless, secure payment solutions, including card payments, digital wallets such as Skrill, eCash solutions like PaysafeCard, and a suite of local payment methods. With approximately 2,800 employees across 12 countries and annualized transactional volume of $167 billion in 2025, Paysafe connects people and businesses worldwide through innovative digital payment experiences. Further information is available at www.paysafe.com.

-

Four out of five bettors have appetite for crypto deposits, with digital asset transactions a likely game-changer for sportsbooks’ customer conversion and retention

JACKSONVILLE, Fla.--(BUSINESS WIRE)--83% of U.S. bettors are keen to use cryptocurrency to fund wagers with online sportsbooks, when permitted, according to research issued today by leading payments platform Paysafe (NYSE: PSFE). The company’s All the Ways Players Pay: Crypto Edition report also suggests that when a state permits crypto payments, sportsbooks supporting deposits by digital assets and even payouts will gain a competitive edge in player acquisition and retention.

As well as bettors in states where crypto deposits aren’t yet permitted – Florida, New Jersey, New York, Ohio, and Pennsylvania – Paysafe surveyed Illinois and Virginia, which have the regulatory latitude to give operators specific permission for crypto-to-cash funding products. Importantly, the study included the two states which explicitly permit crypto deposits, Colorado and Wyoming, where 59% and 45% of bettors, respectively, have already funded a bet with a digital asset.

With 64% of active U.S. bettors owning cryptocurrency, deposits using digital assets would almost certainly trend even higher in other states when permitted. In New York, 92% of players have appetite for crypto deposits, with demand in Illinois and Florida almost as high (88% in both).

When permitted, crypto would be a top-3 payment method for funding wagers, with 45% of players listing crypto as a preference after digital wallets (favored by 55%) and debit cards (50%). In New York, crypto would be second only to wallets (54% versus 59%), with a similar dynamic evident in Illinois, where 52% list crypto as a preference compared to 58% digital wallets.

Despite crypto’s potential to rival wallets and bank cards, other payment methods would remain relevant. Even if digital assets were permitted, credit cards (a preference for 37%) and pay-by-bank solutions and bank transfers (also 37%) would still be relatively popular. And even niche payment options would not be completely overshadowed if crypto were thrown into the transactional mix, with almost a quarter of bettors (23%) still listing local payment methods like peer-to-peer apps and 14% eCash solutions like PaysafeCash.

Players also have interest in cashing-out their winnings in crypto, which is not yet permitted by any state. Well over eight out of 10 bettors (85%) are keen for crypto withdrawals.

Given bettor appetite for cashing-out and crypto funding, it’s unsurprising that digital assets would play an influential role in their selection of a new sportsbook. While brand trust dominates sportsbook choice (prioritized by 36%), crypto payment factors are almost as important, including seamless crypto withdrawals (prioritized by 29%), ability to transact with crypto or other preferred payment methods (28%), and seamless crypto deposits (26%).

Crypto payments’ value extends to player retention. Seven out of 10 players (71%) feel that transacting using digital assets would improve their overall betting experience, with just 18% disagreeing and the remaining 11% unsure.

While crypto will invariably enhance customer stickiness, operators need to carefully evaluate crypto payment products as a poor transactional experience will risk churn, with 71% likely to abandon a sportsbook as a result. Players in some states are even less forgiving, especially New York (80% would switch brands), but also Florida and Illinois (75% in both).

Zak Cutler, President of Global Gaming at Paysafe, commented: “While crypto payments are only currently permitted in a relatively modest cohort of U.S. states, our latest research indicates that there’s strong player appetite for crypto at the cashier in not just these jurisdictions but across the broader market. As regulation evolves and as more iGaming markets embrace digital assets’ impressive value at the cashier, we’re confident that crypto will not just become an important payment method, but arguably pivotal to the industry’s transactional future.”

Disclaimer

Neither Paysafe nor any of its affiliates endorse or promote any form of wagering or gambling. Please note that all forms of gambling and betting (online and otherwise) carry with them inherent financial risk and risk of financial loss. Any gambling or betting activities should be exercised responsibly and with moderation in compliance with all applicable laws and regulations.

About Paysafe’s ‘All the Ways Players Pay: Crypto Edition’ research report

The report was based on a survey conducted in March 2026 on behalf of Paysafe by Sapio Research among 2,550 respondents of legal gambling age across nine U.S. states with regulated online sports-betting (Colorado, Florida, Illinois, New Jersey, New York, Ohio, Pennsylvania, Virginia, and Wyoming). All respondents either actively bet online or intended to within the next 12 months.

Download the full report: https://www.paysafe.com/en/all-the-ways-players-pay-crypto-2026/

About Paysafe

Paysafe is a global payments platform powering the experience economy, with a strong focus on the iGaming, video gaming, e-commerce, online trading, retail, travel and hospitality sectors. With 30 years of expertise in payment technology, Paysafe helps businesses and consumers lift every experience through seamless, secure payment solutions, including card payments, digital wallets such as Skrill, eCash solutions like PaysafeCard, and a suite of local payment methods. With approximately 2,800 employees across 12 countries and annualized transactional volume of $167 billion in 2025, Paysafe connects people and businesses worldwide through innovative digital payment experiences.

More News From Paysafe

Back to Newsroom

Paysafe (NYSE: PSFE), a global payments platform, is taking its technology to the heart of America’s biggest soccer summer, fueling a 39-day, 15,000-mile streamed road trip powered by viral creators Woody & Kleiny.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611493001/en/

Woody & Kleiny’s ‘In A State’ tour brings 39 days, 15,000 miles and nonstop live streaming to the heart of America’s biggest soccer summer. Powered by Paysafe and Skrill to connect fans, creators and local businesses in real time.

Known as the ‘In A State’ tour, this record-breaking journey streams live on Kick and TikTok from June 11, as Woody & Kleiny tear through major cities including Los Angeles, Arlington, Boston and East Rutherford, engaging soccer fans and shining a spotlight on the businesses that make these places tick. The tour will also raise awareness and funds for Prostate Cancer UK, supporting life-saving research, earlier diagnosis and better outcomes for men affected by prostate cancer, which is now the most common cancer in the UK and the only major cancer without a screening program.

Paysafe is the payments engine sponsoring the tour, putting its processing solutions for businesses and its consumer facing digital wallet, Skrill, center stage. Through 24/7 live streaming, in-person activations and creator-led content, Paysafe’s technology will come to life in the most authentic setting imaginable: the real-world energy of America’s biggest soccer tournament.

Woody & Kleiny have built one of the world's largest creator communities, reaching more than 50 million followers across online platforms and generating over 45 billion views.

Paysafe Spotlights Local Businesses

Paysafe will spotlight local businesses, including bars, restaurants, hotels, and retailers, across the route. Woody & Kleiny will showcase Paysafe-powered payment solutions for local merchants via live interactions.

As part of its broader commitment to supporting businesses, Paysafe provides integrated payment solutions tailored to the needs of local merchants. This includes POS technology such as payment devices, competitive payment processing offerings, and value-added services designed to help businesses operate more efficiently. Through these activations, Paysafe will demonstrate how its solutions enable businesses to streamline operations, manage peak demand, and deliver seamless payment experiences.

Skrill: The Wallet That Moves at the Speed of the Game

Paysafe’s digital wallet Skrill will be front and center across the entire ‘In A State’ tour. From fan giveaways to real-time digital payments, Skrill will enable fast, secure transactions within high-energy environments. Fans will interact with Skrill through on-the-ground activations, digital rewards, and integrated content moments — proving that a great digital wallet doesn’t just make payments easier, it makes every experience better.

Through these activations, Skrill will play a visible role in powering fan engagement, from rewarding participation to enabling seamless transactions in real time, demonstrating how the digital wallet can enhance every moment of the fan journey.

“This tour puts Paysafe and Skrill at the heart of the action, powering the moments that matter most,” said Alisa Barber, Chief Marketing Officer at Paysafe. “Woody & Kleiny have an extraordinary ability to turn everyday life into must-watch content and combining that with our technology demonstrates how seamless payments can lift every experience.”

The stream will be complemented by daily YouTube recaps, short-form social content, celebrity appearances and real-time fan engagement — reaching audiences across the globe. Paysafe branding will be unmissable throughout: on the tour bus, across activations, and at the center of every major match-day moment.

For Paysafe, this tour shows how world-class payment technology, the right partners and the biggest sporting event of the decade can come together to create something genuinely extraordinary, while also raising vital awareness and funds for prostate cancer. Fans can donate to Prostate Cancer UK via the official Woody & Kleiny GoFundMe page.

Follow, watch and engage with the tour across Woody & Kleiny, Paysafe and Skrill’s social channels.

Tour Route and Key Stops

Woody & Kleiny will travel through major U.S. cities, where soccer fans will be gathering throughout the tournament. Key stops include:

Los Angeles (June 12), Arlington, TX (June 17), Boston (June 23) East Rutherford, NJ on June 25 and 27 Other cities as the tournament unfolds. About Skrill

Skrill is a leading digital wallet within the Paysafe experience offering, enabling customers to make fast, secure payments and money transfers worldwide, whether they’re transacting with online sports betting and iGaming brands, trading forex and financial assets, sending money to family and friends or shopping online.

About Paysafe

Paysafe is a global payments platform powering the experience economy, with a strong focus on the iGaming, video gaming, e-commerce, online trading, retail, travel and hospitality sectors. With 30 years of expertise in payment technology, Paysafe helps businesses and consumers lift every experience through seamless, secure payment solutions, including card payments, digital wallets such as Skrill, eCash solutions like PaysafeCard, and a suite of local payment methods. With approximately 2,800 employees across 12 countries and annualized transactional volume of $167 billion in 2025, Paysafe connects people and businesses worldwide through innovative digital payment experiences.

About Woody & Kleiny

Woody & Kleiny are one of the most watched entertainment duos in the world, known for creating viral moments that regularly take over the internet. The pair have built a global audience through high-energy, light-hearted content designed purely to entertain and make people laugh, often at each other’s expense, with their unpredictable challenges, pranks and social experiments becoming hugely popular on leading social media platforms.

Across TikTok, YouTube, Instagram, Facebook and Snapchat, Woody & Kleiny have amassed more than 50 million followers and 47 billion views, with no sign of slowing down ahead of their tour of the United States this summer.

While best known for short-form viral entertainment, In A State marks their biggest and most ambitious project to date, taking their audience from short-form internet moments into a 39-day, 24/7 live-streamed journey across America.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260611493001/en/

March 16, 2026 06:55 ET  | Source: iQIYI, Inc.

BEIJING, March 16, 2026 (GLOBE NEWSWIRE) -- iQIYI, Inc. (Nasdaq: IQ) (“iQIYI” or the “Company”), a leading provider of online entertainment video services in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the Securities and Exchange Commission on March 16, 2026, U.S. Eastern Time. The annual report can be accessed on the Company’s investor relations website at http://ir.iqiyi.com.

The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to Investor Relations Department, iQIYI, Inc., 4/F, iQIYI Youth Center, Yoolee Plaza, No. 21, North Road of Workers' Stadium, Chaoyang District, Beijing 100027, People’s Republic of China.

About iQIYI, Inc.

iQIYI, Inc. is a leading provider of online entertainment video services in China. It combines creative talent with technology to foster an environment for continuous innovation and the production of blockbuster content. It produces, aggregates and distributes a wide variety of professionally produced content, as well as a broad spectrum of other video content in a variety of formats. iQIYI distinguishes itself in the online entertainment industry by its leading technology platform powered by advanced AI, big data analytics and other core proprietary technologies. Over time, iQIYI has built a massive user base and developed a diversified monetization model including membership services, online advertising services, content distribution, online games, talent agency, experience business, etc.

For more information, please contact:
Investor Relations
iQIYI, Inc.
[email protected]

Source: iQIYI, Inc.

March 30, 2026 06:03 ET  | Source: iQIYI, Inc.

BEIJING, March 30, 2026 (GLOBE NEWSWIRE) -- iQIYI, Inc. (Nasdaq: IQ) (“iQIYI” or the “Company”), a leading provider of online entertainment video services in China, today announced its latest corporate and business developments, including a proposed listing on the Main Board of the Hong Kong Stock Exchange (the “Proposed Listing”), the adoption of a share repurchase program, and the open commercial testing of its proprietary AI agents Nadou Pro.

Proposed Listing

A listing application form has been submitted to the Hong Kong Stock Exchange (the “HKEX”) on a confidential basis to apply for the listing of, and permission to deal in, the Class A ordinary shares of the Company on the HKEX. The Proposed Listing aims to enhance the Company’s access to the capital market in Hong Kong, broaden the Company’s investor base by increasing exposure to Asia-based institutional and retail investors, and strengthen the Company’s international profile.

Details of the Proposed Listing have not yet been finalized. The Proposed Listing is subject to, among others, the obtaining of approvals from the HKEX, the completion of the filing with the China Securities Regulatory Commission, and the final decision of the Company. There is no assurance that the Proposed Listing will take place or when it may take place.

This announcement shall not constitute an offer to sell or a solicitation of an offer to purchase any securities, in the United States or elsewhere, and shall not constitute an offer, solicitation or sale of the securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

Share Repurchase Program

On March 30, 2026, the Company’s board of directors approved a share repurchase program, under which the Company is authorized to repurchase up to US$100 million of its shares (including in the form of ADSs) in the next 18 months. The share repurchase program became effective immediately upon approval. The share repurchase program aims to demonstrate the Company’s confidence in its long-term business prospect and to deliver value to shareholders.

The Company’s proposed repurchases may be made from time to time through open market transactions at prevailing market prices, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The Company’s board of directors will review the share repurchase program periodically, and may authorize adjustments of its terms and size. The Company expects to fund the repurchase under the share repurchase program with its existing cash balance.

Launch of Proprietary AI Agents Nadou Pro

The Company recently launched open commercial testing for Nadou Pro, its proprietary AI agents and the first in China designed specifically for professional long-form video generation. By integrating leading foundation models with iQIYI’s deep expertise in premium content production, Nadou Pro effectively streamlines the entire production pipeline—from initial creative idea to final video generation.

About iQIYI, Inc.

iQIYI, Inc. is a leading provider of online entertainment video services in China. It combines creative talent with technology to foster an environment for continuous innovation and the production of blockbuster content. It produces, aggregates and distributes a wide variety of professionally produced content, as well as a broad spectrum of other video content in a variety of formats. iQIYI distinguishes itself in the online entertainment industry by its leading technology platform powered by advanced AI, big data analytics and other core proprietary technologies. Over time, iQIYI has built a massive user base and developed a diversified monetization model including membership services, online advertising services, content distribution, online games, talent agency, experience business, etc.

For more information, please contact:
Investor Relations
iQIYI, Inc.
[email protected]

Streaming platform shifts toward AI-generated content and social features while facing pressure from short-video rivals Summary

AI-generated films and new incentives could reshape iQIYI’s growth strategy

iQIYI IQ is signaling a potentially major strategic shift as management leans into artificial intelligence to reshape how films and shows are created, positioning the company for what CEO Gong Yu described as a once-in-a-decade transition. Speaking at the company's annual content showcase in Beijing, Gong indicated that AI could eventually generate a meaningful portion of iQIYI's content from scratch, as the platform evolves from a traditional streaming service into a more social-media-oriented destination centered on AI-driven content. The move comes as the Baidu-backed company navigates ongoing pressure from short-video platforms, which have contributed to a prolonged revenue slowdown and pushed management to reconsider the balance between professionally produced programming and emerging formats.

As part of this transition, iQIYI introduced its Nadou Pro system, which the company says is capable of handling nearly the full production pipeline, including scriptwriting, storyboarding, and final rendering. Management outlined plans to begin scaling AI-generated content quickly, starting with a slate of 16 Nadou-produced films spanning genres such as sci-fi and anime, while targeting the release of a commercially successful AI-generated film as early as this summer. To expand its creator ecosystem, iQIYI is offering an additional 20% share of advertising and membership revenue to AI content producers, alongside the development of a standalone app designed to let users interact with characters through short-form video clips. The Nadou platform incorporates AI models from companies including Alibaba, ByteDance, and Kuaishou, with iQIYI highlighting its existing relationships with professional filmmakers as a potential advantage in building a more integrated production workflow.

This strategic pivot is unfolding against a challenging financial backdrop, with first-quarter revenue projected to decline 13% amid intensifying competition from short-form video platforms. In response, iQIYI is also targeting areas that could provide incremental growth, including overseas markets where membership revenue increased more than 30% last year, albeit from a smaller base, and physical entertainment initiatives such as its indoor theme park in Yangzhou. The company has also filed for a Hong Kong listing, which could broaden its access to regional capital as it executes this transition. At the same time, iQIYI's approach aligns with a broader industry trend, as global players such as Netflix and Amazon continue exploring AI to potentially reduce production costs and enhance content development capabilities.

, /PRNewswire/ -- On April 24, iQIYI, China's leading online entertainment platform, launched "Voices of Youth", a brand-new variety show bringing together 25 young artists spanning vocalists, idol artists, crossover actors, and emerging musicians to form China's first pop performance choral show. Before its premiere, the show topped the Most Anticipated Variety Shows chart on Weibo, China's leading social media platform, multiple times and debuted simultaneously on iQIYI International across markets to strong reception.

"Voices of Youth" introduces a first-of-its-kind "pop performance choral" format, moving beyond both traditional choral conventions and domestic idol competition shows. Integrating SATB (Soprano, Alto, Tenor, Bass) four-part professional choral arrangements with dance and theatrical staging, the show uses mixed-voice ensembles to enrich the musical texture and elevate the visual impact, delivering an immersive audiovisual experience that bridges choral artistry and popular culture. Grounded in the creative energy of today's Chinese youth, the format speaks a musical language familiar to international audiences.

The show follows 25 young artists through intensive training, competitive stage performance, and international cultural exchange, chronicling their journey from strangers into a unified ensemble and capturing the passion and camaraderie that define the experience of youth.

In its song selection and arrangements, the show is closely attuned to the aesthetic preferences of younger audiences, bringing choral music out of the concert hall and into the mainstream. The production team applies a world-class choral training framework across varieties of full-scale stage productions this season, holding every performance to rigorous artistic standards. Beyond the stage, the show serves as a platform for international cultural exchange, bringing together leading choral ensembles from China and abroad to showcase the musical talent and spirit of today's Chinese youth, and to build genuine connections between young artists across cultures.

"Voices of Youth" is the latest example of iQIYI's investment in original variety show, developing new formats that go beyond existing IP. By pairing a universally accessible art form, the series is part of iQIYI's broader effort to bring Chinese creative talent to a global audience.

CONTACT: iQIYI Press
[email protected]

SOURCE iQIYI

BEIJING, May 18, 2026 (GLOBE NEWSWIRE) -- iQIYI, Inc. (Nasdaq: IQ) (“iQIYI” or the “Company”), a leading provider of online entertainment video services in China, today announced its unaudited financial results for the first quarter ended March 31, 2026.

First Quarter 2026 Highlights

Total revenues were RMB6.23 billion (US$902.5 million1), decreasing 13% year over year.Operating loss was RMB228.4 million (US$33.1 million) and operating loss margin was 4%, compared to operating income of RMB341.9 million and operating income margin of 5% in the same period in 2025.Non-GAAP operating loss2 was RMB148.6 million (US$21.5 million) and non-GAAP operating loss margin was 2%, compared to non-GAAP operating income of RMB458.5 million and non-GAAP operating income margin of 6% in the same period in 2025.Net loss attributable to iQIYI was RMB294.6 million (US$42.7 million), compared to net income attributable to iQIYI of RMB182.1 million in the same period in 2025.Non-GAAP net loss attributable to iQIYI2 was RMB234.4 million (US$34.0 million), compared to non-GAAP net income attributable to iQIYI of RMB304.4 million in the same period in 2025. “We are reinforcing our core strengths, unlocking new growth drivers, and building for the long term. In the first quarter, our hit drama lineup drove sequential membership revenue growth and cemented our leadership in domestic viewership market share, according to Enlightent. Meanwhile, our overseas business sustained its robust growth momentum, achieving record membership revenue this quarter,” commented Mr. Yu Gong, Founder, Director, and Chief Executive Officer of iQIYI. “Looking ahead, we are leveraging AI to reduce content production costs, accelerate production cycles, and expand our content ecosystem.”

“In March, we announced a proposed listing on the Main Board of the Hong Kong Stock Exchange, and our first share repurchase program, demonstrating our commitment to delivering shareholder value,” commented Ms. Ying Zeng, Interim Chief Financial Officer of iQIYI.

First Quarter 2026 Financial Highlights

  Three Months Ended(Amounts in thousands of Renminbi (“RMB”), except for per ADS data, unaudited) March 31,
 December 31, March 31,  2025
 2025 2026  RMB
 RMB RMBTotal revenues 7,186,469  6,794,198  6,225,775         Operating income/(loss) 341,897  55,395  (228,433)Operating income/(loss) (non-GAAP) 458,535  143,515  (148,599)        Net income/(loss) attributable to iQIYI, Inc. 182,145  (5,816) (294,581)Net income/(loss) attributable to iQIYI, Inc. (non-GAAP) 304,420  109,668  (234,352)        Diluted net income/(loss) per ADS 0.19  (0.01) (0.31)Diluted net income/(loss) per ADS (non-GAAP)2 0.31  0.11  (0.24)           Footnotes:
[1] Unless otherwise noted, RMB to USD was converted at an exchange rate of RMB6.8980 as of March 31, 2026, as set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System. Translations are provided solely for the convenience of the reader.
[2] Non-GAAP measures are defined in the Non-GAAP Financial Measures section (see also “Reconciliations of Non-GAAP Financial Measures to the Nearest Comparable GAAP Measures” for more details).

First Quarter 2026 Financial Results

Total revenues reached RMB6.23 billion (US$902.5 million), decreasing 13% year over year.

Membership services revenue was RMB4.20 billion (US$608.8 million), decreasing 5% year over year, primarily due to a lighter content slate compared to the same period last year.

Online advertising services revenue was RMB1.24 billion (US$179.9 million), decreasing 7% year over year, as some advertisers adjusted their advertising and promotion strategies in response to macro pressures.

Content distribution revenue was RMB358.7 million (US$52.0 million), decreasing 43% year over year, primarily due to the decrease in barter transactions.

Other revenues were RMB426.7 million (US$61.9 million), decreasing 49% year over year, primarily due to the alteration of certain business cooperation arrangement.

Cost of revenues was RMB5.23 billion (US$758.7 million), decreasing 3% year over year. Content costs as a component of cost of revenues were RMB3.74 billion (US$542.8 million), decreasing 1% year over year.

Selling, general and administrative expenses were RMB816.5 million (US$118.4 million), decreasing 20% year over year. The decrease was primarily attributable to disciplined marketing spending.

Research and development expenses were RMB404.2 million (US$58.6 million), decreasing 2% year over year.

Operating loss was RMB228.4 million (US$33.1 million), compared to operating income of RMB341.9 million in the same period in 2025. Operating loss margin was 4%, compared to operating income margin of 5% in the same period in 2025.

Non-GAAP operating loss was RMB148.6 million (US$21.5 million), compared to non-GAAP operating income of RMB458.5 million in the same period in 2025. Non-GAAP operating loss margin was 2%, compared to non-GAAP operating income margin of 6% in the same period in 2025.

Total other expense was RMB28.0 million (US$4.1 million), decreasing 76% year over year, primarily due to gain from foreign exchange and decrease in interest expense.

Loss before income taxes was RMB256.4 million (US$37.2 million), compared to income before income taxes of RMB227.2 million in the same period in 2025.

Income tax expense was RMB37.2 million (US$5.4 million), compared to income tax expense of RMB41.6 million in the same period in 2025.

Net loss attributable to iQIYI was RMB294.6 million (US$42.7 million), compared to net income attributable to iQIYI of RMB182.1 million in the same period in 2025. Diluted net loss attributable to iQIYI per ADS was RMB0.31 (US$0.04) for the first quarter of 2026, compared to diluted net income attributable to iQIYI per ADS of RMB0.19 in the same period of 2025.

Non-GAAP net loss attributable to iQIYI was RMB234.4 million (US$34.0 million), compared to non-GAAP net income attributable to iQIYI of RMB304.4 million in the same period in 2025. Non-GAAP diluted net loss attributable to iQIYI per ADS was RMB0.24 (US$0.04), compared to non-GAAP diluted net income attributable to iQIYI per ADS of RMB0.31 in the same period of 2025.

Net cash provided by operating activities was RMB186.4 million (US$27.0 million), compared to net cash provided by operating activities of RMB339.0 million in the same period of 2025. Free cash flow was RMB109.8 million (US$15.9 million), compared to free cash flow of RMB307.7 million in the same period of 2025.

As of March 31, 2026, the Company had cash, cash equivalents, restricted cash, short-term investments and long-term restricted cash included in prepayments and other assets of RMB3.99 billion (US$578.4 million). In addition, as of the same date, the Company had an aggregate loan of US$636.6 million to PAG, classified as a non-current asset under prepayments and other assets.

Repurchase of 6.50% Convertible Senior Notes due 2028

In March 2026, the Company completed the repurchase right offer for its 6.50% convertible senior notes due 2028 (the “2028 Notes”). An aggregate principal amount of US$207.8 million of the 2028 Notes were validly surrendered and repurchased with the same amount. Following settlement of the repurchase, US$259,000 aggregate principal amount of the 2028 Notes remains outstanding and continues to be subject to the existing terms of the Indenture and the 2028 Notes.

As of March 31, 2026, US$0.1 million principal amount of the 2026 Notes, US$522.5 million principal amount of the PAG Notes, US$0.3 million principal amount of the 2028 Notes, and US$350.0 million principal amount of the 2030 Notes remained outstanding.

Share Repurchase Program

Pursuant to the Company’s share repurchase program of up to US$100 million adopted in March 2026 and effective through September 2027, as of the date of this earnings release, the Company has repurchased a total of approximately 6.5 million ADSs for a total cost of US$8.0 million.

Conference Call Information

iQIYI’s management will hold an earnings conference call at 7:00 AM on May 18, 2026, U.S. Eastern Time (7:00 PM on May 18, 2026, Beijing Time).

Please register in advance of the conference using the link provided below. Upon registering, you will be provided with participant dial-in numbers, passcode and unique access PIN by a calendar invite.

Participant Online Registration: https://s1.c-conf.com/diamondpass/10054471-y7rp1m.html

It will automatically direct you to the registration page of "iQIYI First Quarter 2026 Earnings Conference Call", where you may fill in your details for RSVP.

In the 10 minutes prior to the call start time, you may use the conference access information (including dial-in number(s), passcode and unique access PIN) provided in the calendar invite that you have received following your pre-registration.

A telephone replay of the call will be available after the conclusion of the conference call through May 25, 2026.

Dial-in numbers for the replay are as follows:
International Dial-in+1 855 883 1031Passcode:10054471   A live and archived webcast of the conference call will be available at http://ir.iqiyi.com/.

About iQIYI, Inc.

iQIYI, Inc. is a leading provider of online entertainment video services in China. It combines creative talent with technology to foster an environment for continuous innovation and the production of blockbuster content. It produces, aggregates and distributes a wide variety of professionally produced content, as well as a broad spectrum of other video content in a variety of formats. iQIYI distinguishes itself in the online entertainment industry by its leading technology platform powered by advanced AI, big data analytics and other core proprietary technologies. Over time, iQIYI has built a massive user base and developed a diversified monetization model including membership services, online advertising services, content distribution, online games, talent agency, experience business, etc.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the quotations from management in this announcement, as well as iQIYI's strategic and operational plans, contain forward-looking statements. iQIYI may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about iQIYI’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: iQIYI’s strategies; iQIYI’s future business development, financial condition and results of operations; iQIYI’s ability to retain and increase the number of users, members and advertising customers, and expand its service offerings; competition in the online entertainment industry; changes in iQIYI's revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online entertainment industry, general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and iQIYI undertakes no duty to update such information, except as required under applicable law.

Non-GAAP Financial Measures

To supplement iQIYI’s consolidated financial results presented in accordance with GAAP, iQIYI uses the following non-GAAP financial measures: non-GAAP operating income/(loss), non-GAAP operating income/(loss) margin, non-GAAP net income/(loss) attributable to iQIYI, non-GAAP diluted net income/(loss) attributable to iQIYI per ADS and free cash flow. The presentation of the non-GAAP financial measure is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.

iQIYI believes that these non-GAAP financial measures provide meaningful supplemental information regarding its operating performance by excluding certain items that may not be indicative of its business operating results, such as operating performance excluding non-cash charges or non-operating in nature. The Company believes that both management and investors benefit from referring to the non-GAAP financial measures in assessing its performance and when planning and forecasting future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to iQIYI’s historical operating performance. The Company believes the non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making. A limitation of using these non-GAAP financial measures is that the non-GAAP measures exclude certain items that have been and will continue to be for the foreseeable future a significant component in the Company’s results of operations. These non-GAAP financial measures presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to the Company’s data.

Non-GAAP operating income/(loss) represents operating income/(loss) excluding share-based compensation expenses, amortization of intangible assets resulting from business combinations.

Non-GAAP net income/(loss) attributable to iQIYI, Inc. represents net income/(loss) attributable to iQIYI, Inc. excluding share-based compensation expenses, amortization of intangible assets resulting from business combinations, disposal gain or loss, impairment of long-term investments, fair value change of long-term investments, adjusted for related income tax effects. iQIYI’s share of equity method investments for these non-GAAP reconciling items, primarily amortization and impairment of intangible assets not on the investees’ books, accretion of their redeemable non-controlling interests, and the gain or loss associated with the issuance of shares by the investees at a price higher or lower than the carrying value per share, adjusted for related income tax effects, are also excluded.

Non-GAAP diluted net income/(loss) per ADS represents diluted net income/(loss) per ADS calculated by dividing non-GAAP net income/(loss) attributable to iQIYI, Inc, by the weighted average number of ordinary shares expressed in ADS.

Free cash flow represents net cash provided by operating activities less capital expenditures.

For more information, please contact:

Investor Relations
iQIYI, Inc.
[email protected]

iQIYI, INC.Condensed Consolidated Statements of Income/(Loss)

(In RMB thousands, except for number of shares and per share data)

     Three Months Ended  March 31, December 31, March 31,  2025 2025 2026  RMB RMB RMB  (Unaudited) (Unaudited) (Unaudited)Revenues:      Membership services 4,399,010  4,105,859  4,199,761 Online advertising services 1,327,827  1,352,811  1,240,611 Content distribution 628,743  787,669  358,749 Others 830,889  547,859  426,654 Total revenues 7,186,469  6,794,198  6,225,775        Operating costs and expenses:      Cost of revenues (5,406,341) (5,376,079) (5,233,486)Selling, general and administrative (1,025,742) (946,184) (816,530)Research and development (412,489) (416,540) (404,192)Total operating costs and expenses (6,844,572) (6,738,803) (6,454,208)Operating income/(loss) 341,897  55,395  (228,433)       Other income/(expense):      Interest income 78,756  84,499  80,459 Interest expense (233,429) (220,278) (213,951)Foreign exchange gain, net 41,889  65,115  89,066 Share of gains/(losses) from equity method investments (3,617) 18  (1,464)Others, net 1,724  43,491  17,936 Total other expense, net (114,677) (27,155) (27,954)       Income/(loss) before income taxes 227,220  28,240  (256,387)Income tax expense (41,590) (35,757) (37,161)       Net income/(loss) 185,630  (7,517) (293,548)Less: Net income attributable to noncontrolling interests 3,485  (1,701) 1,033 Net income/(loss) attributable to iQIYI, Inc. 182,145  (5,816) (294,581)Net income/(loss) attributable to ordinary shareholders 182,145  (5,816) (294,581)       Net income/(loss) per share for Class A and Class B ordinary shares:      Basic 0.03  (0.00) (0.04)Diluted 0.03  (0.00) (0.04)       Net income/(loss) per ADS (1 ADS equals 7 Class A ordinary shares):      Basic 0.19  (0.01) (0.31)Diluted 0.19  (0.01) (0.31)       Weighted average number of Class A and Class B ordinary shares used in net income/(loss) per share computation:      Basic 6,740,810,595  6,753,258,796  6,756,463,437 Diluted 6,780,303,294  6,753,258,796  6,756,463,437            iQIYI, INC.
Condensed Consolidated Balance Sheets(In RMB thousands, except for number of shares and per share data)

       December 31, March 31,  2025
 2026
  RMB RMB    (Unaudited)ASSETS    Current assets:    Cash and cash equivalents 4,354,275  2,941,129 Restricted cash 23,123  379,928 Short-term investments 314,819  668,710 Accounts receivable, net 2,522,668  2,560,064 Prepayments and other assets 2,406,222  2,354,731 Amounts due from related parties 221,681  205,000 Licensed copyrights, net 447,507  613,868 Total current assets 10,290,295  9,723,430      Non-current assets:    Fixed assets, net 903,427  896,350 Long-term investments 1,773,309  1,789,985 Deferred tax assets, net 20,773  17,323 Licensed copyrights, net 5,962,954  6,139,134 Intangible assets, net 217,085  225,868 Produced content, net 14,578,037  14,580,537 Prepayments and other assets 8,458,312  8,378,389 Operating lease assets 489,720  483,737 Goodwill 3,820,823  3,820,823 Amounts due from related parties 167,000  119,000 Total non-current assets 36,391,440  36,451,146      Total assets 46,681,735  46,174,576      LIABILITIES AND SHAREHOLDERS’ EQUITY    Current liabilities:    Accounts and notes payable 6,652,432  7,292,405 Amounts due to related parties 3,717,283  3,733,236 Customer advances and deferred revenue 4,160,459  4,330,435 Convertible senior notes, current portion 1,459,151  1,085 Short-term loans 2,493,100  2,335,598 Long-term loans, current portion 738,391  1,142,966 Operating lease liabilities, current portion 84,174  83,565 Accrued expenses and other liabilities 2,762,317  2,678,198 Total current liabilities 22,067,307  21,597,488 Non-current liabilities:    Long-term loans 3,368,876  3,658,848 Convertible senior notes 6,711,948  6,671,382 Amounts due to related parties 38,192  32,863 Operating lease liabilities 340,256  328,005 Other non-current liabilities 846,230  863,223 Total non-current liabilities 11,305,502  11,554,321      Total liabilities 33,372,809  33,151,809           Shareholders’ equity:         Class A ordinary shares 239  240 Class B ordinary shares 193  193 Additional paid-in capital 56,026,232  56,107,367 Accumulated deficit (44,015,680) (44,310,261)Accumulated other comprehensive income 1,305,542  1,271,379 Non-controlling interests (7,600) (46,151)Total shareholders’ equity 13,308,926  13,022,767      Total liabilities and shareholders' equity 46,681,735  46,174,576         iQIYI, INC.Condensed Consolidated Statements of Cash Flows

(In RMB thousands)

   Three Months Ended March 31, December 31, March 31, 2025
 2025
 2026
 RMB RMB RMB (Unaudited) (Unaudited) (Unaudited)      Net cash provided by operating activities338,950  47,163  186,448 Net cash used for investing activities(1,2)(30,136) (947,000) (274,759)Net cash provided by/(used for) financing activities860,477  518,404  (933,140)Effect of exchange rate changes on cash, cash equivalents and restricted cash(1,232) (10,206) (34,896)Net increase/(decrease) in cash, cash equivalents and restricted cash1,168,059  (391,639) (1,056,347)Cash, cash equivalents and restricted cash at the beginning of the period3,590,331  4,769,377  4,377,738 Cash, cash equivalents and restricted cash at the end of the period4,758,390  4,377,738  3,321,391 Reconciliation of cash and cash equivalents and restricted cash:

     Cash and cash equivalents4,320,028  4,354,275  2,941,129 Restricted cash1,899  23,123  379,928 Long-term restricted cash436,463  340  334 Total cash and cash equivalents and restricted cash shown in the statements of cash flows4,758,390  4,377,738  3,321,391       Net cash provided by operating activities338,950  47,163  186,448 Less: Capital expenditures(2)(31,252) (20,413) (76,698)Free cash flow307,698  26,750  109,750  (1) Net cash used for investing activities primarily consists of net cash flows from loans provided to related party, investing in debt securities, purchase of long-term investments and capital expenditures.
(2) Capital expenditures are incurred primarily in connection with construction in process, computers and servers.

iQIYI, INC.Reconciliations of Non-GAAP Financial Measures to the Nearest Comparable GAAP Measures

(Amounts in thousands of Renminbi (“RMB”), except for per ADS information, unaudited)

   Three Months Ended March 31, December 31, March 31, 2025
 2025
 2026
RMB RMB RMB      Operating income/(loss)341,897  55,395  (228,433)Add: Share-based compensation expenses115,105  86,587  78,301 Add: Amortization of intangible assets(1)1,533  1,533  1,533 Operating income/(loss) (non-GAAP)458,535  143,515  (148,599)      Net income/(loss) attributable to iQIYI, Inc.182,145  (5,816) (294,581)Add: Share-based compensation expenses115,105  86,587  78,301 Add: Amortization of intangible assets(1)1,533  1,533  1,533 Add: Impairment of long-term investments2,000  9,990  9,009 Add: Fair value loss/(gain) of long-term investments(1,740) 17,374  (28,614)Add: Reconciling items on equity method investments(2)5,377  -  - Net income/(loss) attributable to iQIYI, Inc. (non-GAAP)304,420  109,668  (234,352)      Diluted net income/(loss) per ADS0.19  (0.01) (0.31)Add: Non-GAAP adjustments to earnings per ADS0.12  0.12  0.07 Diluted net income/(loss) per ADS (non-GAAP)0.31  0.11  (0.24)          (1) This represents amortization of intangible assets resulting from business combinations.
(2) This represents iQIYI’s share of equity method investments for other non-GAAP reconciling items, primarily amortization and impairment of intangible assets not on the investee’s books, accretion of their redeemable noncontrolling interests, and the gain or loss associated with the issuance of shares by the investees at a price higher or lower than the carrying value per share.

iQIYI, Inc. (IQ) Q1 2026 Earnings Call Transcript